Advertisement

PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules

  • Shibo Qi
  • Susan Hoppmann
  • Yingding Xu
  • Zhen ChengEmail author
Research Article
  • 43 Downloads

Abstract

Purpose

Previous studies has demonstrated the utility of human epidermal growth factor receptor type 2 (HER2) as an attractive target for cancer molecular imaging and therapy. An affibody protein with strong binding affinity for HER2, ZHER2:342, has been reported. Various methods of chelator conjugation for radiolabeling HER2 affibody molecules have been described in the literature including N-terminal conjugation, C-terminal conjugation, and other methods. Cu-64 has recently been extensively evaluated due to its half-life, decay properties, and availability. Our goal was to optimize the radiolabeling method of this affibody molecule with Cu-64, and translate a positron emission tomography (PET) probe with the best in vivo performance to clinical PET imaging of HER2-positive cancers.

Procedures

In our study, three anti-HER2 affibody proteins-based PET probes were prepared, and their in vivo performance was evaluated in mice bearing HER2-positive subcutaneous SKOV3 tumors. The affibody analogues, Ac-Cys-ZHER2:342, Ac-ZHER2:342(Cys39), and Ac-ZHER2:342-Cys, were synthesized using the solid phase peptide synthesis method. The purified small proteins were site-specifically conjugated with the maleimide-functionalized chelator, 1,4,7,10-tetraazacyclododecane-1,4,7-tris- aceticacid-10-maleimidethylacetamide (maleimido-mono-amide-DOTA). The resulting DOTA-affibody conjugates were then radiolabeled with Cu-64. Cell uptake assay of the resulting PET probes, [64Cu]DOTA-Cys-ZHER2:342, [64Cu]DOTA-ZHER2:342(Cys39), and [64Cu]DOTA-ZHER2:342-Cys, was performed in HER2-positive human ovarian SKOV3 carcinoma cells at 4 and 37 °C. The binding affinities of the radiolabeled peptides were tested by cell saturation assay using SKOV3 cells. PET imaging, biodistribution, and metabolic stability studies were performed in mice bearing SKOV3 tumors.

Results

Cell uptake assays showed high and specific uptake by incubation of Cu-64-labeled affibodies with SKOV3 cells. The affinities (KD) of the PET radio probes as tested by cell saturation analysis were in the low nanomolar range with the ranking of [64Cu]DOTA-Cys-ZHER2:342 (25.2 ± 9.2 nM) ≈ [64Cu]DOTA-ZHER2:342-Cys (32.6 ± 14.7 nM) > [64Cu]DOTA-ZHER2:342(Cys39) (77.6 ± 22.2 nM). In vitro stability and in vivo metabolite analysis study revealed that all three probes were stable enough for in vivo imaging applications, while [64Cu]DOTA-Cys-ZHER2:342 showed the highest stability. In vivo small-animal PET further demonstrated fast tumor targeting, good tumor accumulation, and good tumor to normal tissue contrast of all three probes. For [64Cu]DOTA-Cys-ZHER2:342, [64Cu]DOTA-ZHER2:342(Cys39), and [64Cu]DOTA-ZHER2:342-Cys, tumor uptake at 24 h are 4.0 ± 1.0 % ID/g, 4.0 ± 0.8 %ID/g, and 4.3 ± 0.7 %ID/g, respectively (mean ± SD, n = 4). Co-injection of the probes with non-labeled anti-HER2 affibody proteins confirmed in vivo specificities of the compounds by tumor uptake reduction.

Conclusions

The three Cu-64-labeled ZHER2:342 analogues all display excellent HER2 targeting ability and tumor PET imaging quality. Although varied in the position of the radiometal labeling of these three Cu-64-labeled ZHER2:342 analogues, there is no significant difference in tumor and normal tissue uptakes among the three probes. [64Cu]DOTA-Cys-ZHER2:342 stands out as the most superior PET probe because of its highest affinities and in vivo stability.

Key words

PET Affibody HER2 Cu-64 Tumor 

Notes

Acknowledgments

This work was supported, in part, by the Department of Radiology, Stanford University (ZC), National Cancer Institute (NCI) 5R01 CA119053 (ZC), a fellowship from China Scholarship Council (to SQ),Tianjin Municipal Education Commission 20140512 (SQ).

Compliance with Ethical Standards

Animal studies were performed based on the protocol approved by the Stanford University Administrative Panels on Laboratory Animal Care (APLAC).

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

11307_2018_1310_MOESM1_ESM.pdf (274 kb)
ESM 1 (PDF 273 kb)

References

  1. 1.
    Corcoran EB, Hanson RN (2014) Imaging EGFR and HER2 by PET and SPECT: a review. Med Res Rev 34:596–643CrossRefGoogle Scholar
  2. 2.
    Parakh S, Gan HK, Parslow AC, Burvenich IJG, Burgess AW, Scott AM (2017) Evolution of anti-HER2 therapies for cancer treatment. Cancer Treat Rev 59:1–21CrossRefGoogle Scholar
  3. 3.
    Löblom J, Feldwisch J, Tolmachev V et al (2010) Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584:2670–2680CrossRefGoogle Scholar
  4. 4.
    Miao Z, Levi J, Cheng Z (2011) Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids 41:1037–1047CrossRefGoogle Scholar
  5. 5.
    Justino CIL, Duarte AC, Rocha-Santos TAP (2015) Analytical applications of affibodies. Trac-trend Anal Chem 65:73–82CrossRefGoogle Scholar
  6. 6.
    Nilsson FY, Tolmachev V (2007) Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel 10:167–175Google Scholar
  7. 7.
    Cheng Z, De Jesus OP, Namavari M et al (2008) Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 49:804–813CrossRefGoogle Scholar
  8. 8.
    Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer-Marek G, Gandjbakhche A, Capala J (2008) Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res 14:3840–3849CrossRefGoogle Scholar
  9. 9.
    Meric-Bernstam F, Hung MC (2006) Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 12:6326–6330CrossRefGoogle Scholar
  10. 10.
    Robert NJ, Favret AM (2007) HER2-positive advanced breast cancer. Hematol Oncol Clin North Am 21:293–302CrossRefGoogle Scholar
  11. 11.
    Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F (2007) HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19:56–62CrossRefGoogle Scholar
  12. 12.
    Ståhl S, Grälund T, Karlström AE et al (2017) Affibody molecules in biotechnological and medical applications. Trends Biotechnol 35:691–712CrossRefGoogle Scholar
  13. 13.
    Namavari M, Padilla De Jesus O, Cheng Z et al (2008) Direct site-specific radiolabeling of an Affibody protein with 4-[18F]fluorobenzaldehyde via oxime chemistry. Mol Imaging Biol 10:177–181CrossRefGoogle Scholar
  14. 14.
    Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J (2008) [18F]FBEM-ZHER2:342-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 35:1008–1018CrossRefGoogle Scholar
  15. 15.
    Miao Z, Ren G, Jiang L, Liu H, Webster JM, Zhang R, Namavari M, Gambhir SS, Syud F, Cheng Z (2011) A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor. Eur J Nucl Med Mol Imaging 38:1977–1984CrossRefGoogle Scholar
  16. 16.
    Rosik D, Thibblin A, Antoni G, Honarvar H, Strand J, Selvaraju RK, Altai M, Orlova A, Eriksson Karlström A, Tolmachev V (2014) Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with 18F-4-fluorobenzaldehyde. Bioconjug Chem 25:82–92CrossRefGoogle Scholar
  17. 17.
    Xu Y, Bai Z, Huang Q, Pan Y, Pan D, Wang L, Yan J, Wang X, Yang R, Yang M (2017) PET of HER2 expression with a novel 18FAl labeled affibody. J Cancer 8:1170–1178CrossRefGoogle Scholar
  18. 18.
    Orlova A, Nilsson FY, Wikman M et al (2006) Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 47:512–519Google Scholar
  19. 19.
    Hofström C, Altai M, Honarvar H, Strand J, Malmberg J, Hosseinimehr SJ, Orlova A, Gräslund T, Tolmachev V (2013) HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [99mTc(CO)3]+-labeled affibody molecules. J Med Chem 56:4966–4974CrossRefGoogle Scholar
  20. 20.
    Zhang J, Zhao X, Wang S, Wang N, Han J, Jia L, Ren X (2015) Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with 99mTc-peptide-ZHER2:342. Nucl Med Biol 42:541–546CrossRefGoogle Scholar
  21. 21.
    Tolmachev V, Nilsson FY, Widström C et al (2006) 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 47:846–853Google Scholar
  22. 22.
    Perols A, Honarvar H, Strand J, Selvaraju R, Orlova A, Eriksson Karlström A, Tolmachev V (2012) Influence of DOTA chelator position on biodistribution and targeting properties of 111In-labeled synthetic anti-HER2 affibody molecules. Bioconjug Chem 23:1661–1670CrossRefGoogle Scholar
  23. 23.
    Fortin MA, Orlova A, Malmstrom PU, Tolmachev V (2007) Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med 19:285–291Google Scholar
  24. 24.
    Altai M, Westerlund K, Velletta J, Mitran B, Honarvar H, Karlström AE (2017) Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting: development of an optimized conjugation protocol and 177Lu labeling. Nucl Med Biol 54:1–9CrossRefGoogle Scholar
  25. 25.
    Orlova A, Magnusson M, Eriksson TLJ, Nilsson M, Larsson B, Höidén-Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, Nilsson FY (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66:4339–4348CrossRefGoogle Scholar
  26. 26.
    Honarvar H, Westerlund K, Altai M et al (2012) Feasibility of affibody molecule-based PNA-mediated radionuclide pretargeting of malignant tumors. Theranostics 6:93–103CrossRefGoogle Scholar
  27. 27.
    Cheng Z, De Jesus OP, Kramer DJ et al (2012) 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 12:316–324CrossRefGoogle Scholar
  28. 28.
    Strand J, Honarvar H, Perols A, Orlova A, Selvaraju RK, Karlström AE, Tolmachev V (2013) Influence of macrocyclic chelators on the targeting properties of 68Ga-labeled synthetic affibody molecules: comparison with 111In-labeled counterparts. PLoS One 8:e70028CrossRefGoogle Scholar
  29. 29.
    Sandberg D, Tolmachev V, Velikyan I, Olofsson H, Wennborg A, Feldwisch J, Carlsson J, Lindman H, Sörensen J (2017) Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the affibody molecule ABY-025 with PET and SPECT. Eur J Nucl Med Mol Imaging 44:1337–1346CrossRefGoogle Scholar
  30. 30.
    Altai M, Honarvar H, Wållberg H, Strand J, Varasteh Z, Rosestedt M, Orlova A, Dunås F, Sandström M, Löfblom J, Tolmachev V, Ståhl S (2014) Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re. Eur J Med Chem 87:519–528CrossRefGoogle Scholar
  31. 31.
    Honarvar H, Müller C, Cohrs S, Haller S, Westerlund K, Karlström AE, van der Meulen NP, Schibli R, Tolmachev V (2017) Evaluation of the first 44Sc-labeled affibody molecule for imaging of HER2-expressing tumors. Nucl Med Biol 45:15–21CrossRefGoogle Scholar
  32. 32.
    Webster JM, Zhang R, Gambhir SS, Cheng Z, Syud FA (2009) Engineered two-helix small proteins for molecular recognition. Chembiochem 10:1293–1296CrossRefGoogle Scholar
  33. 33.
    Qi S, Miao Z, Liu H, Xu Y, Feng Y, Cheng Z (2012) Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors. Bioconjug Chem 23:1149–1156CrossRefGoogle Scholar
  34. 34.
    Massoud TF, Gambhir SS (2013) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545–580CrossRefGoogle Scholar
  35. 35.
    Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B, Widmark O, Fant G, Feldwisch J, Tolmachev V (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem 19:235–243CrossRefGoogle Scholar
  36. 36.
    Blower PJ, Lewis JS, Zweit J (1996) Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 23:957–980CrossRefGoogle Scholar
  37. 37.
    Shokeen M, Anderson CJ (2009) Molecular imaging of cancer with copper-64 raidiopharmaceuticals and positron emission tomography (PET). Accounts Chem Res 42:832–841CrossRefGoogle Scholar
  38. 38.
    Cai Z, Anderson CJ (2013) Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals. J Label Compd Radiopharm 57:224–230CrossRefGoogle Scholar

Copyright information

© World Molecular Imaging Society 2019

Authors and Affiliations

  1. 1.School of Environmental and Chemical EngineeringTianjin Polytechnic UniversityTianjinChina
  2. 2.Molecular Imaging Program at Stanford (MIPS), Department of Radiology, and Bio-X Program, Canary Center at Stanford for Cancer Early DetectionStanford UniversityStanfordUSA

Personalised recommendations